Peter Nygren1, Rolf Larsson. 1. University Hospital, Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, S-751 85, Uppsala, Sweden +46 18 611 49 41 ; +46 18 51 92 37 ; peter.nygren@medsci.uu.se.
Abstract
BACKGROUND: The selection of cancer drugs for an individual patient is still based mostly on cancer type and stage. Predictive tests are needed to make individualized and more efficient pharmacological cancer treatment possible. OBJECTIVE: To provide an overview of available, possible future development and principles for development of predictive tests for individualized selection of cancer drugs. METHODS: Overview of published data. RESULTS/ CONCLUSION: Despite increased knowledge in cancer biology, only limited progress has been made in the development and use of predictive tests. However, rapid progress in this field will be possible using already available and emerging technologies, but requires a paradigm shift in principles for the development and use of cancer drugs. Assessment of drug activity in intact tumor cells and tumor cell gene expression signatures are considered to have greatest potential for the development of versatile predictive tests.
BACKGROUND: The selection of cancer drugs for an individual patient is still based mostly on cancer type and stage. Predictive tests are needed to make individualized and more efficient pharmacological cancer treatment possible. OBJECTIVE: To provide an overview of available, possible future development and principles for development of predictive tests for individualized selection of cancer drugs. METHODS: Overview of published data. RESULTS/ CONCLUSION: Despite increased knowledge in cancer biology, only limited progress has been made in the development and use of predictive tests. However, rapid progress in this field will be possible using already available and emerging technologies, but requires a paradigm shift in principles for the development and use of cancer drugs. Assessment of drug activity in intact tumor cells and tumor cell gene expression signatures are considered to have greatest potential for the development of versatile predictive tests.
Authors: Carmela Fimognari; Monia Lenzi; Lorenzo Ferruzzi; Eleonora Turrini; Paolo Scartezzini; Ferruccio Poli; Roberto Gotti; Alessandra Guerrini; Giovanni Carulli; Virginia Ottaviano; Giorgio Cantelli-Forti; Patrizia Hrelia Journal: PLoS One Date: 2011-06-28 Impact factor: 3.240
Authors: A Eriksson; A Österroos; S Hassan; J Gullbo; L Rickardson; M Jarvius; P Nygren; M Fryknäs; M Höglund; R Larsson Journal: Blood Cancer J Date: 2015-04-17 Impact factor: 11.037
Authors: Frank Christian Kischkel; Julia Eich; Carina I Meyer; Paula Weidemüller; Jens Krapfl; Rauaa Yassin-Kelepir; Laura Job; Marius Fraefel; Ioana Braicu; Annette Kopp-Schneider; Jalid Sehouli; Rudy Leon De Wilde Journal: PeerJ Date: 2017-03-02 Impact factor: 2.984
Authors: Charlotte Carlier; Sara Strese; Kristina Viktorsson; Ebba Velander; Peter Nygren; Maria Uustalu; Therese Juntti; Rolf Lewensohn; Rolf Larsson; Jack Spira; Elly De Vlieghere; Wim P Ceelen; Joachim Gullbo Journal: Oncotarget Date: 2016-09-13